<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512278</url>
  </required_header>
  <id_info>
    <org_study_id>PARTNER</org_study_id>
    <nct_id>NCT00512278</nct_id>
  </id_info>
  <brief_title>Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C</brief_title>
  <acronym>PARTNER</acronym>
  <official_title>Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nizar Zein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate in subjects receiving their first course of
      peg-interferon α-2b plus ribavirin therapy for chronic HCV infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate in subjects receiving their first course of
      peg-interferon α-2b plus ribavirin therapy for chronic HCV infection (genotype 1) whether the
      addition of infliximab to a standard regimen of pegylated interferon α-2b in combination with
      ribavirin:

        -  increases the proportion of subjects attaining a sustained virological response SVR
           (undetectable blood Hepatitis C viral load 6 months after treatment)

        -  improves the safety profile compared to the same regimen without infliximab
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment.</measure>
    <time_frame>72 Weeks from initiation of treatment</time_frame>
    <description>A comparison of the Proportion of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of TreatmentSVR in both study arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Sustained Virological Response (SVR)</measure>
    <time_frame>24 weeks after completion of all study medications</time_frame>
    <description>HCV RNA negativity at 24 weeks after completion of all study medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Comparison of the Percentage of Participants With Non-detectable HCV-RNA After 24 Weeks of Therapy.</measure>
    <time_frame>24 weeks</time_frame>
    <description>A comparison of the proportion of the subject population with non-detectable HCV-RNA after 24 wks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Serious Adverse Events</measure>
    <time_frame>72 Weeks from initiation of treatment</time_frame>
    <description>The severity of adverse events was graded according to modified World Health Organization grades as mild, moderate, severe, or life-threatening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Medically Significant Infections</measure>
    <time_frame>72 weeks from initiation of treatment</time_frame>
    <description>Medically significant infection was defined as an infection requiring the use of intravenous antibiotics or hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, &gt;18 years of age with proven chronic (greater than 6 months)
             hepatitis C infection (genotype 1) who have never been treated with pegylated
             interferon α-2b and /or ribavirin.

        Criteria for inclusion in this trial are as follows:

          -  Male or female, 18 years of age or older

          -  Positive HCV RNA, Genotype 1, treatment naïve (never received pegylated interferon and
             / or ribavirin)

          -  Evidence of chronic HCV infection for at least six months prior to screening

          -  Findings on liver biopsy within the past 36 months that are consistent with the
             presence of chronic hepatitis C infection.

          -  Negative hepatitis B surface antigen

          -  No evidence of hemochromatosis

          -  Hemoglobin ≥12 g/dL for females and ≥13 g/dL for males

          -  WBC ≥3.0 x 109/L and neutrophils ≥1.5 x 109/L

          -  Platelets ≥80 x109/L

          -  Direct Bilirubin WNL +/- 50% of central laboratory normal range. Total bilirubin ≤1.6.

          -  Albumin within normal limits

          -  Serum creatinine within normal limits.

          -  Serum thyroid stimulating hormone (TSH) levels within normal limits

          -  Men and women of childbearing potential must use two forms of adequate birth control
             measures for the duration of the study and should continue such precautions for 6
             months after receiving the last infusion.

          -  Subjects with a history of mild depression may be considered for entry into this
             study.

          -  No history of latent or active TB.

        Exclusion Criteria:

          -  Women who are pregnant, nursing, or planning pregnancy within 6 months after the last
             infusion and men with partners who are pregnant at baseline or intend to become
             pregnant within 6 months after the last infusion.

          -  Known allergy against infliximab, ribavirin, or pegylated interferon

          -  Decompensated liver disease characterized as decreased hepatic synthetic functioning
             with abnormal albumin and bilirubin levels, prolonged prothrombin time or
             complications including ascites or recent variceal bleeding

          -  have a history of latent or active granulomatous infection, including TB,
             histoplasmosis, or coccidiomycosis (Valley Fever)

          -  History of autoimmune hepatitis or a history of poorly controlled autoimmune disease

          -  Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic
             steroids

          -  Previous treatment with monoclonal antibodies or antibody fragments

          -  History of receiving human/murine recombinant products or a known allergy to murine
             products

          -  Documentation of seropositive for human immunodeficiency virus (HIV)

          -  History of alcohol or substance abuse within the preceding 6 months that, in the
             opinion of the investigator, may increase the risks associated with study
             participation or study agent administration, or may interfere with interpretation of
             results

          -  History of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the
             previous 3 months

          -  Opportunistic infection within 6 months prior to screening

          -  History of lymphoproliferative disease

          -  Currently have any known malignancy or have a history of malignancy within the
             previous 5 years, with the exception of basal cell or squamous cell carcinoma of the
             skin that has been fully excised with no evidence of recurrence

          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral
             disease

          -  Treatment with any other therapeutic agent targeted at reducing TNF within 3 months of
             screening

          -  Presence of a transplanted solid organ

          -  Concomitant diagnosis or history of congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nizar N Zein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Center for Liver Disease and Transplantation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>440292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>August 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2017</results_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Nizar Zein</investigator_full_name>
    <investigator_title>Associate Professor of Medicine; Chief, Section of Hepatobiliary Diseases; Medical Director of Liver Transplantation</investigator_title>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment 2007-2011 Data Lock Nov 22, 2012 Sites
The Cleveland Clinic
University Hospitals of Cleveland
Cedar Sinai Medical Center, Los Angeles,
The Liver Institute at Methodist Dallas
Brooke Army Medical Center, San Antonio
Advanced Medical Research Center, Daytona Beach.
University of Louisville, Louisville</recruitment_details>
      <pre_assignment_details>220 subjects screened and 149 randomized Reasons for exclusion were multiple including malignancy, liver failure, negative HCV RNA, abnormal lab values, poorly controlled diabetes, psych disorders, positive tuberculosis skin test, seizure disorder, inability to get labs or liver biopsy, pregnancy, patient declining, other (cardiomypathy, MS, etc.)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A Infliximab</title>
          <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
        </group>
        <group group_id="P2">
          <title>B Placebo</title>
          <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed similar to infliximab for patients in arm A of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A Infliximab</title>
          <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
        </group>
        <group group_id="B2">
          <title>B Placebo</title>
          <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed similar to infliximab for patients in arm A of the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="9.78"/>
                    <measurement group_id="B2" value="47.2" spread="9.38"/>
                    <measurement group_id="B3" value="46.9" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment.</title>
        <description>A comparison of the Proportion of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of TreatmentSVR in both study arms</description>
        <time_frame>72 Weeks from initiation of treatment</time_frame>
        <population>Included all patients who received at least one dose of treatment in both study arms</population>
        <group_list>
          <group group_id="O1">
            <title>A Infliximab</title>
            <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
          </group>
          <group group_id="O2">
            <title>B Placebo</title>
            <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients received triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed similar to infliximab for patients in arm A of the study</description>
          </group>
        </group_list>
        <measure>
          <title>A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment.</title>
          <description>A comparison of the Proportion of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of TreatmentSVR in both study arms</description>
          <population>Included all patients who received at least one dose of treatment in both study arms</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming a 25% difference in the rate of SVR between the PEG INF/RBV plus infliximab group (70%) and the PEG INF/RBV (45%) group, a power of 0.85 and an alpha level of 0.05, 75 patients for each group was estimated</non_inferiority_desc>
            <p_value>0.718</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Comparison of the Percentage of Participants With Non-detectable HCV-RNA After 24 Weeks of Therapy.</title>
        <description>A comparison of the proportion of the subject population with non-detectable HCV-RNA after 24 wks of therapy.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Infliximab</title>
            <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
          </group>
          <group group_id="O2">
            <title>B Placebo</title>
            <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed simialr to infliximab for patients in arm A of the study</description>
          </group>
        </group_list>
        <measure>
          <title>A Comparison of the Percentage of Participants With Non-detectable HCV-RNA After 24 Weeks of Therapy.</title>
          <description>A comparison of the proportion of the subject population with non-detectable HCV-RNA after 24 wks of therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Sustained Virological Response (SVR)</title>
        <description>HCV RNA negativity at 24 weeks after completion of all study medications</description>
        <time_frame>24 weeks after completion of all study medications</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Infliximab</title>
            <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
          </group>
          <group group_id="O2">
            <title>B Placebo</title>
            <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed simialr to infliximab for patients in arm A of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Sustained Virological Response (SVR)</title>
          <description>HCV RNA negativity at 24 weeks after completion of all study medications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SVR was the primary outcome to calculate sample size. Assuming a 25% difference in the rate of SVR between the the two groups, a power of 0.85 and an alpha level of 0.05, 75 patients for each group was estimated. This analysis included patients randomized and received at least one dose of study drugs. A 2-sided probability value of &lt; 0.05 was considered statistically significant. Univariate and multivariable logistic regression were used for factors associated with an SVR.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming a 25% difference in the rate of SVR between the PEG INF/RBV plus infliximab group (70%) and the PEG INF/RBV (45%) group, a power of 0.85 and an alpha level of 0.05, 75 patients for each group was estimated.</non_inferiority_desc>
            <p_value>0.718</p_value>
            <p_value_desc>Univariate and multivariable logistic regression were used for factors associated with an SVR.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Serious Adverse Events</title>
        <description>The severity of adverse events was graded according to modified World Health Organization grades as mild, moderate, severe, or life-threatening</description>
        <time_frame>72 Weeks from initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Infliximab</title>
            <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
          </group>
          <group group_id="O2">
            <title>B Placebo</title>
            <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed simialr to infliximab for patients in arm A of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Serious Adverse Events</title>
          <description>The severity of adverse events was graded according to modified World Health Organization grades as mild, moderate, severe, or life-threatening</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Medically Significant Infections</title>
        <description>Medically significant infection was defined as an infection requiring the use of intravenous antibiotics or hospitalization.</description>
        <time_frame>72 weeks from initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Infliximab</title>
            <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
          </group>
          <group group_id="O2">
            <title>B Placebo</title>
            <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed simialr to infliximab for patients in arm A of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Medically Significant Infections</title>
          <description>Medically significant infection was defined as an infection requiring the use of intravenous antibiotics or hospitalization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A Infliximab</title>
          <description>Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
Infliximab : Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/infliximab) at approved doses</description>
        </group>
        <group group_id="E2">
          <title>B Placebo</title>
          <description>Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
Placebo : Placebo
All patients recieved triple therapy (pegylated interferon (PEG IFN)/ribavirin/placebo) at approved doses. Placebo infusions were timed simialr to infliximab for patients in arm A of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>hemoglobin less than 8.5g/dL</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Etiology not determined.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Medically Significant Infections</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Influenza-Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any Infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nizar Zein</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-6126</phone>
      <email>zeinn@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

